C
SNDX icon

Covestor’s Syndax Pharmaceuticals SNDX Stock Holding History

Covestor’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
29
+21
+263% +$437 ﹤0.01% 2332
2026
Q1 		$0 Hold
8
– – ﹤0.01% 2730
2025
Q4 		$0 Hold
8
– – ﹤0.01% 2699
2025
Q3 		$0 Sell
8
-29
-78% -$380 ﹤0.01% 2729
2025
Q2 		$0 Buy
37
+28
+311% +$308 ﹤0.01% 2715
2025
Q1 		$0 Buy
9
+4
+80% +$56 ﹤0.01% 2690
2024
Q4 		$0 Buy
5
+1
+25% +$17 ﹤0.01% 2695
2024
Q3 		$0 Sell
4
-1
-20% -$21 ﹤0.01% 2718
2024
Q2 		$0 Hold
5
– – ﹤0.01% 2710
2024
Q1 		$0 Hold
5
– – ﹤0.01% 2693
2023
Q4 		$0 Sell
5
-1
-17% -$15 ﹤0.01% 2672
2023
Q3 		$0 Hold
6
– – ﹤0.01% 2665
2023
Q2 		$0 Sell
6
-13
-68% -$271 ﹤0.01% 2605
2023
Q1 		$0 Buy
19
+5
+36% +$124 ﹤0.01% 2538
2022
Q4 		$0 Sell
14
-1
-7% -$23 ﹤0.01% 2561
2022
Q3 		$0 Buy
15
+3
+25% +$67 ﹤0.01% 2554
2022
Q2 		$0 Buy
+12
New +$200 ﹤0.01% 2336

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Covestor's SNDX Position: Q2 2026 in Review

Covestor increased its Syndax Pharmaceuticals (SNDX) stake by 263% in Q2 2026, buying an estimated $437 and bringing the position to 29 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Covestor first reported a position in SNDX in Q2 2022 and has held it in 17 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Covestor held 29 shares of Syndax Pharmaceuticals worth $1K as of Q2 2026.
  • Covestor bought 21 Syndax Pharmaceuticals shares in Q2 2026, an estimated $437.
  • Syndax Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2332 holding.
  • Covestor first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.